Joseph A. Aisner

Q: What Schools Are Affiliated With Joseph A. Aisner

Joseph A. Aisner is affiliated with the following schools: University of Maryland, College Park, Rutgers University

Joseph A. Aisner's AcademicInfluence.com Rankings

Joseph A. Aisner

Philosophy

#6178

World Rank

#9172

Historical Rank

Logic

#3367

World Rank

#4514

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Joseph A. Aisner Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Joseph A. Aisner's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. (1999) (1410)
Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. (1977) (395)
Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. (1984) (311)
Invasive aspergillosis in acute leukemia: correlation with nose cultures and antibiotic use. (1979) (258)
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. (1989) (254)
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. (2000) (242)
Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. (1985) (201)
Aspergillus infections in cancer patients. Association with fireproofing materials in a new hospital. (1976) (192)
Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations. (1980) (189)
Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. (1997) (182)
A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors (2010) (179)
Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma (2001) (169)
A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. (1983) (164)
Carcinomatous Leptomeningitis in Small Cell Lung Cancer: A Clinicopathologic Review of the National Cancer Institute Experience (1982) (160)
Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. (1983) (153)
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. (1993) (153)
Current state of immunotherapy for non-small cell lung cancer. (2007) (149)
Megestrol acetate in cancer anorexia and weight loss (2010) (147)
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. (2018) (147)
Overview of the changing paradigm in cancer treatment: oral chemotherapy. (2007) (146)
Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations. (1982) (130)
Frozen autologous platelet transfusion for patients with leukemia. (1978) (129)
Current approach to malignant mesothelioma of the pleura. (1995) (123)
Esophagoscopy as a source of Pseudomonas aeruginosa sepsis in patients with acute leukemia: the need for sterilization of endoscopes. (1974) (119)
Alloimmunization following platelet transfusion: the absence of a dose- response relationship (1981) (117)
Alloimmunization following prophylactic granulocyte transfusion. (1979) (115)
DEXTROMETHORPHAN IS EFFECTIVE IN THE TREATMENT OF SUBACUTE METHOTREXATE NEUROTOXICITY (2002) (115)
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. (1997) (114)
Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. (1987) (112)
A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. (1988) (112)
High-dose megestrol acetate. A possible treatment for cachexia. (1986) (111)
Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized (1981) (108)
Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. (1983) (108)
Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. (1998) (106)
Commentary: current status of chemotherapy for non-small cell lung cancer. (1981) (106)
High-time chemotherapy or high time for low dose. (2000) (105)
Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer (2010) (104)
Torulopsis glabrata infections in patients with cancer. Increasing incidence and relationship to colonization. (1976) (103)
Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. (1999) (102)
Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion (1983) (96)
Staging, prognostic factors, and special considerations in small cell lung cancer. (1988) (95)
First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors (2017) (94)
Performance status assessment among oncology patients: a review. (1986) (93)
The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. (2000) (90)
Meperidine for the treatment of shaking chills and fever. (1980) (90)
Pericardial window for malignant pericardial effusion. (1980) (86)
High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. (1981) (84)
Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B. (1993) (84)
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. (1987) (83)
A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5‐drug chemotherapy for advanced breast cancer A Cancer and Leukemia Group B study (1984) (77)
High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. (2002) (75)
Comprehensive textbook of thoracic oncology (1996) (74)
CT of peritoneal mesothelioma: analysis of eight cases. (1982) (73)
Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. (2002) (73)
Clinical experience with transfusion of granulocytes obtained by continuous flow filtration leukopheresis. (1975) (73)
Chemotherapy in the treatment of malignant mesothelioma. (1981) (72)
Peritoneal mesothelioma: natural history and response to chemotherapy. (1983) (72)
Computed tomographic evaluation of carcinoma of the cervix. (1982) (70)
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. (2020) (70)
Phase I clinical and pharmacologic trial of carboplatin daily for 5 days. (1984) (69)
Surgery in acute leukemia: A review of 167 operations in thrombocytopenic patients (1987) (69)
Overcoming bcl-2- and p53-mediated resistance in prostate cancer. (1999) (68)
Dihydro‐5‐azacytidine and cisplatin in the treatment of malignant mesothelioma (1998) (68)
Antiemetic studies: a methodological discussion. (1986) (67)
Changing face of small-cell lung cancer: real and artifact. (2006) (67)
Malignant mesothelioma. Current status and future prospects. (1978) (64)
Pregnancy outcome in patients treated for Hodgkin's disease. (1993) (64)
Clinical Experience with Transfusion of Cryopreserved Platelets (1976) (64)
Successful transfusion of platelets cryopreserved for more than 3 years. (1979) (63)
Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat. (1994) (62)
The pharmacology of carboplatin. (1989) (62)
Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia. (1976) (62)
Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. (1986) (62)
Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized. (1981) (61)
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers (2016) (61)
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. (1986) (60)
Frozen Autologous Platelets in the Supportive Care of Patients with Leukemia (2003) (58)
Empiric antibiotic therapy. (1978) (58)
Tamoxifen withdrawal response. Report of a case. (1989) (57)
Etoposide: current status and future perspectives in the management of malignant neoplasms (2004) (55)
Alloimmunization prevents the migration of transfused indium-111-labeled granulocytes to sites of infection. (1983) (54)
Reduction in Tumor Volume by Cone Beam Computed Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy. (2015) (54)
Carboplatin in malignant mesothelioma: A phase II study of the cancer and leukemia Group B (2004) (53)
Small cell carcinoma of the lung: influence of age on treatment outcome. (1987) (51)
Mitomycin C and vinblastine chemotherapy for advanced breast cancer (1981) (50)
Treatment of cancer anorexia with megestrol acetate: impact on quality of life. (1990) (48)
Dosimetric Predictors of Symptomatic Cardiac Events After Conventional‐Dose Chemoradiation Therapy for Inoperable NSCLC (2018) (47)
A Standardized Technique for Efficient Platelet and Leukocyte Collection Using the Model 30 Blood Processor (2003) (47)
Etoposide. Current and future status (1991) (47)
High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. (1980) (46)
Mesothelioma following Wilms' tumor in childhood (1984) (46)
Volume determinations in computed tomography. (1982) (46)
Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. (1999) (45)
Doxorubicin, cyclophosphamide, and whole body hyperthermia for treatment of advanced soft tissue sarcoma (1984) (44)
Appetite stimulation and weight gain with megestrol acetate. (1990) (43)
Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation. (2015) (42)
Granulocyte transfusion therapy and amphotericin B: Adverse reactions? (1989) (42)
CT of malignant pleural mesothelioma. (1983) (41)
A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies (2006) (41)
Chemotherapy versus chemoimmunotherapy for small‐cell undifferentiated carcinoma of the lung (1980) (41)
Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors (1984) (41)
Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer. (2015) (41)
Transient neutropenia induced by transfusion of blood exposed to nylon fiber filters. (1975) (40)
Megestrol acetate-induced differentiation of 3T3-L1 adipocytes in vitro. (1988) (40)
Current status of high-dose progestins in breast cancer. (1990) (40)
A novel pharmacodynamically based approach to dose optimization of carboplatin when used in combination with etoposide. (1989) (40)
Potential HLA‐matched platelet donor availability for alloimmunized patients (1983) (40)
High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. (1984) (39)
Granulocyte Transfusions: Evaluation of Factors Influencing Results and a Comparison of Filtration and Intermittent Centrifugation Leukapheresis (1978) (39)
Trimethoprim/sulfamethoxazole versus placebo: a double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung. (1983) (38)
High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients (1984) (38)
Mastectomy as an adjuvant to chemotherapy for locally advanced or metastatic breast cancer. (1982) (38)
Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. (1990) (37)
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration (2019) (37)
Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. (1995) (37)
High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. (1999) (36)
Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide (1982) (35)
Possible pulmonary toxicity secondary to vinblastine (1982) (35)
Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. (1995) (34)
Phase II trial of carboplatin in non-small cell lung cancer. (1986) (33)
Studies of high-dose megestrol acetate: potential applications in cachexia. (1988) (33)
Carboplatin: the experience in head and neck cancer. (1989) (33)
A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer. (1989) (32)
High-dose megestrol acetate for the treatment of advanced breast cancer: dose and toxicities. (1987) (32)
Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-disease small-cell lung cancer: a Cancer and Leukemia Group B pilot study. (1992) (32)
The Effect of Hydroxyethyl Starch on In Vitro Platelet and Granulocyte Function (2003) (31)
Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081. (1987) (31)
Special studies of the Hickman catheter of a patient with recurrent bacteremia and candidemia. (1986) (31)
Clinical and Biological Activity of Soy Protein Powder Supplementation in Healthy Male Volunteers (2007) (31)
Chemoradiotherapy for the treatment of regionally advanced head and neck cancers. (1994) (31)
Multiple sequential biomarkers in monitoring patients with carcinoma of the lung. (1984) (31)
Reversal of granulocyte adherence to nylon fibers using local anesthetic agents: possible application to filtration leukapheresis. (1977) (30)
Computed tomography of the chest in small cell lung cancer: potential new prognostic signs. (1984) (30)
Alloimmunization following platelet transfusion: the absence of a dose-response relationship. (1981) (30)
Leptomeningeal carcinomatosis in small cell carcinoma of the lung. (1981) (30)
Sustained post‐transfusion granulocyte count increments following transfusion of leukocytes obtained from donors with chronic myelogenous leukemia (1983) (30)
Physiologic response and toxicity in patients undergoing whole-body hyperthermia for the treatment of cancer. (1981) (30)
Restaging laparotomy in the management of the non-Hodgkin lymphomas. (1982) (30)
Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer (2005) (29)
Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). (2019) (29)
Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004 World Health Organization in Patients Treated with Octreotide and Prednisone: An Eastern Cooperative Oncology Group Study (2010) (29)
Cisplatin for small-cell lung cancer. (1989) (28)
Treatment of chemotherapy extravasation: current status. (1984) (28)
Use of the computed tomographic whole body scanner to stage and follow patients with advanced ovarian carcinoma. (1980) (27)
A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. (2011) (27)
Pharmacokinetics of paclitaxel and carboplatin in combination. (1995) (27)
Patterns of recurrence for cancer of the lung and esophagus (1983) (27)
Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma. (2003) (27)
Chemotherapy Versus Chemoimmunotherapy (CAF v CAFVP v CMF Each t MER) for Metastatic Carcinoma of the Breast: A CALGB Study (1987) (26)
A clinical program of platelet cryopreservation. (1982) (26)
Abdominal CT in the staging of small-cell carcinoma of the lung: incidence of metastases and effect on prognosis. (1987) (26)
Transtracheal selective bronchial brushing for pulmonary infiltrates in patients with cancer. (1976) (26)
High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia. (1980) (26)
Platelet transfusion therapy for patients with leukemia. (1978) (26)
Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma (2001) (25)
cis-Dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma: a phase II study. (1979) (25)
Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer. (1995) (25)
Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease. (1996) (25)
Combined chemotherapy and radiation in locally advanced non-small cell lung cancer. (1994) (24)
High-dose megestrol acetate in the treatment of postmenopausal women with advanced breast cancer. (1986) (24)
High-dose megestrol acetate in the treatment of advanced breast cancer. (1988) (24)
Torulopsis glabrata pneumonitis in patients with cancer. Report of three cases. (1974) (24)
Identification of new drugs in small cell lung cancer: phase II agents first? (1987) (23)
Carboplatin in the treatment of squamous cell head and neck cancers. (1992) (23)
Appetite stimulation with megestrol acetate in cachectic cancer patients. (1986) (23)
Horizontal pigmented banding of the nails in association with adriamycin chemotherapy. (1977) (23)
Lung cancer as a complication of prolonged survival in patients with lymphoma. (1982) (23)
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. (2003) (23)
Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer. (1983) (23)
The Effect of Dimethyl Sulfoxide on In Vitro Platelet Function (1976) (22)
CCNU, vincristine, methotrexate, and procarbazine treatment of relapsed small cell lung carcinoma. (1982) (22)
Meningeal carcinomatosis from small cell carcinoma of the lung. Consequence of improved survival. (1979) (22)
A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib: a Brief Report. (2019) (22)
Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors. (2010) (21)
Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501) (2014) (21)
Platinum compounds. (1989) (21)
PLATELET CRYOPRESERVATION USING DIMETHYL SULFOXIDE (1983) (20)
Daily Image Guidance With Cone Beam Computed Tomography May Reduce Radiation Pneumonitis in Unresectable Non-Small Cell Lung Cancer. (2018) (20)
Doxorubicin, cyclophosphamide, etoposide and platinum, doxorubicin, cyclophosphamide and etoposide for small-cell carcinoma of the lung. (1986) (20)
Tamoxifen in advanced male breast cancer. (1979) (20)
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors (2019) (20)
Combined modalities in the treatment of head and neck cancers. (1995) (19)
Lung cancer: recent changes and expectations of improvements. (1993) (19)
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia (2008) (19)
Platelet transfusion therapy. (1977) (18)
High-dose chemotherapy without autologous bone marrow transplantation in melanoma. (1986) (18)
Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial. (2003) (18)
Long-term results of a combined modality approach in treating inflammatory carcinoma of the breast. (1991) (18)
A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck. (1997) (18)
242 Promising long term outcome of weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC) (1997) (17)
The use of computed body tomography in malignant melanoma. (1988) (17)
First-inHuman Clinical Trial of Oral ONC 201 in Patients with Refractory Solid Tumors (2019) (17)
European School of Oncology. First Euro-American Forum on Lung Cancer Treatment. (1994) (17)
Phase I trial of N-methylformamide (NMF, NSC 3051). (1985) (16)
Renal failure and platinum pharmacokinetics in three patients treated with cis-diamminedichloroplatinum(II) and whole-body hyperthermia (2004) (16)
Immunomodulation of Interleukin‐2 by Cyclophosphamide: A Phase IB Trial (1993) (15)
Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen. (1997) (15)
A Comparison of Platelets Prepared by the Haemonetics Model 30 and Multiunit Bag Plateletpheresis (1979) (15)
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors (2019) (15)
Vandetanib Plus Chemotherapy for Induction Followed by Vandetanib or Placebo As Maintenance for Patients with Advanced Non–Small-Cell Lung Cancer: A Randomized Phase 2 PrECOG Study (PrE0501) (2013) (15)
Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma (2004) (15)
A phase I trial of continuous infusion VP16-213 (Etoposide) (2004) (14)
The ineffectiveness of random donor platelet transfusion in splenectomized, alloimmunized recipients (1984) (14)
Sample Size and Power Calculations (2021) (14)
Tumors of the Pleura and Mediastinum (2008) (14)
Nuclear Factor-κB Modulation in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia (2008) (13)
Exposure-response and PD-L1 expression analysis of second-line avelumab in patients with advanced NSCLC: Data from the JAVELIN Solid Tumor trial. (2017) (13)
A study of HLA antigens and haplotypes in a population of Caucasians with acute non-lymphocytic leukemia. (1979) (12)
Phase I trial of dihydroxyanthracenedione. (1981) (12)
Gravity leukapheresis--a simple method of leukocyte collection for transfusion or in vitro study. (1979) (12)
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. (2003) (12)
Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non–Small Cell Lung Cancer (2016) (12)
Mastectomy as an adjunct to combination chemotherapy. (1978) (12)
Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data. (2018) (11)
Pemetrexed for diffuse malignant pleural mesothelioma. (2002) (11)
Phase I trial of pentamethylmelamine in patients with previously treated malignancies. (1980) (11)
Phase I trial of menogaril administered as an intermittent daily infusion for 5 days. (1986) (11)
Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer (1992) (11)
Phase I trial of aclacinomycin A. (1982) (10)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
Treatment of limited-disease small cell lung cancer. (1992) (10)
Modern radiotherapy using image guidance for unresectable non-small cell lung cancer can improve outcomes in patients treated with chemoradiation therapy. (2016) (10)
Donor reaction to hydroxyethyl starch during granulocytap heresis (1984) (10)
Initial Observations on the Effects of Δ9‐Tetrahydrocannabinol on the Plasma Pharmacokinetics of Cyclophosphamide and Doxorubicin (1981) (10)
A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443. (1990) (10)
Effect of 13-cis-retinoic acid and α-interferon on transforming growth factor in patients with rising prostate-specific antigen (1997) (10)
Acquired toxoplasmic lymphadenitis with demonstration of the cyst form. (1983) (9)
Protein Calorie Malnutrition and Cancer Therapy (1992) (9)
Current status of granulocyte transfusion therapy. (1977) (9)
Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer. (2019) (9)
A Novel Paradigm in the Treatment of Oligometastatic Non-small Cell Lung Cancer (2008) (9)
Chemoimmunotherapy for advanced breast cancer: A randomized comparison of 6 combinations (CMF, CAF vs CAFVP) each with or without MER immunotherapy. A CALGB study (1981) (9)
Paclitaxel and carboplatin in metastatic non-small cell lung cancer: preliminary results of a phase I study. (1996) (9)
Paravertebral Nerve Block With Liposomal Bupivacaine for Pain Control Following Video-Assisted Thoracoscopic Surgery and Thoracotomy. (2020) (9)
Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes. (2018) (8)
Cancer Treatment Research (1980) (8)
The ineffectiveness of random donor platelet transfusion in splenectomized, alloimmunized recipients. (1984) (8)
Phase II study of caracemide in advanced or recurrent non-small cell lung cancer. (1987) (8)
Modulation of autophagy with hydroxychloroquine in patients with advanced non-small cell lung cancer (NSCLC): A phase Ib study. (2018) (8)
Evaluation of gravity leukapheresis and comparison with intermittent centrifugation leukapheresis (1981) (8)
Orthostatic hypotension during combination chemotherapy with vincristine (NSC-67574). (1974) (8)
A phase II trail of vindesine in patients with refractory small-cell carcinoma of the lung. (1982) (8)
Staging of small cell lung cancer: do we need a new staging system? (1989) (8)
A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide (2004) (8)
Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory small cell carcinoma of the lung (1983) (8)
A phase II trial of m‐AMSA in the treatment of advanced gynecologic malignancies (1982) (7)
COMPUTED TOMOGRAPHIC DEMONSTRATION OF PERITONEAL MESOTHELIOMA (1981) (7)
Increased leukocyte alkaline phosphatase activity following transfusion of leukocytes from a patient with chronic myelogenous leukemia. (1979) (7)
Phase II trial of AMSA in patients with refractory small cell carcinoma of the lung. (1981) (7)
Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma. (1982) (7)
Combined-modality therapies for non-small cell lung cancer. (1992) (7)
CTEP #8342 autophagy modulation with antiangiogenic therapy: A phase I trial of sunitinib (Su) and hydroxychloroquine (HCQ). (2013) (6)
Aziridinylbenzoquinone (AZQ) in advanced breast cancer: a Cancer and Leukemia group B phase II trial. (1982) (6)
Therapeutic approach to malignant mesothelioma. (1989) (6)
Statistical Design and Analysis of Clinical Trials: Principles and Methods (2015) (6)
Infections in patients with non-small-cell lung cancer treated with intensive induction chemotherapy. (1986) (6)
Paclitaxel in head and neck and other cancers: future prospects. (1997) (6)
Histocompatible platelet transfusion for patients with leukemia (1982) (6)
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer (2020) (6)
Phase II evaluation of AMSA in patients with stage III--IV malignant melanoma. (1982) (6)
Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer. (1987) (6)
CT Screening for Lung Cancer: Are We Ready for Wide-Scale Application? (2007) (6)
Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma. (1980) (6)
Asbestos-Related Malignancy (1987) (6)
Small bowel obstruction as a late complication of the treatment of Hodgkin's disease. (1990) (5)
Combining radiation therapy and immunotherapy for lung cancers: a narrative review (2020) (5)
Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion (2004) (5)
Phase I Neoadjuvant Study of Intravesical Recombinant Fowlpox-GM-CSF (rF-GMCSF) or Fowlpox-TRICOM (rF-TRICOM) in Patients with Bladder Carcinoma (2019) (5)
Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naive advanced non-small cell lung cancer (NSCLC). (2013) (5)
Erratum to current state of immunotherapy for non-small cell lung cancer. (2017) (5)
Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma (2004) (5)
Cyclophosphamide and dimethylsulfoxide in the treatment of squamous carcinoma of the lung (1981) (4)
Phase II trial of methyl-G (methylglyoxal bis-guanylhydrazone) in patients with metastatic renal cell carcinoma. (1981) (4)
Phase I/II study of cyclophosphamide, doxorubicin, fluorouracil, and leucovorin for treatment of metastatic adenocarcinoma. (1991) (4)
Treatment of advanced non-small cell lung cancer with bisantrene. (1983) (4)
High-dose 6-mercaptopurine in advanced refractory cancer. (1978) (4)
Doxorubicin, cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer (2004) (4)
The potential of megestrol acetate in the treatment of cancer cachexia. (1989) (4)
Human Pharmacokinetics and Correlation With Clinical Toxicities of the Anthracycline Antibiotic Menogaril (7-Omen) (1985) (4)
Inflammatory changes related to active tuberculosis: confusion with oat cell carcinoma of the lung on cytology specimens. (1978) (4)
Combination chemotherapy of advanced breast cancer with adriamycin and VP 16-213 (1979) (4)
Failure of Postfiltration Leukapheresis Plasma to Increase Granulocyte Yields (1977) (4)
A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer (1991) (4)
Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution (2019) (4)
Breast cancer therapy in the elderly. (1993) (3)
Clinical characteristics and dose-volume histogram parameters associated with the development of pleural effusions in non-small cell lung cancer patients treated with chemoradiation therapy (2016) (3)
Current issues associated with oral chemotherapy: a roundtable discussion. (2007) (3)
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer (2013) (3)
PRELIMINARY-OBSERVATIONS ON THE EFFECTS OF DIMETHYLSULFOXIDE ON THE METABOLISM AND DISTRIBUTION OF ADRIAMYCIN (1981) (3)
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors and melanoma. (2012) (3)
Nutritional concerns in cancer patients. (1989) (3)
Current staging of lung cancer: an overview of current and newer approaches. (1989) (3)
Paclitaxel in head and neck cancer and other tumor types: chairmen's introduction. (1997) (3)
Phase II trial of aclarubicin in advanced breast cancer: a cancer and leukemia group B study. (1983) (3)
Abstract PulmonaryThoracoscopic staging and diagnosis for lung cancer: University of Maryland experience (1994) (3)
Rational Approach to Granulocyte Transfusion Therapy (1980) (3)
Choline-magnesium trisalicylate modulates acute myelogenous leukemia gene expression during induction chemotherapy (2017) (3)
Variations in Initiation Dates of Chemotherapy and Radiation Therapy for Definitive Management of Inoperable Non–Small Cell Lung Cancer Are Associated With Decreases in Overall Survival (2018) (3)
Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004 World Health Organization in Patients Treated with Octreotide and Prednisone: (2011) (3)
Streptozotocin: an inactive agent in small cell carcinoma. (1979) (3)
Current approaches to small cell lung cancer (1992) (3)
Cranial irradiation in adults diagnosed with acute myelogenous leukemia presenting with hyperleukocytosis and neurologic dysfunction (2014) (3)
Strategies for new drug identification in small cell lung cancer (1993) (2)
Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. (2018) (2)
Use of computed body tomography in malignant melanoma (1988) (2)
Topoisomerase Inhibitors Conference University of Maryland Cancer Center, 27-30 October 1993, Monterey, California, USA (1994) (2)
Should we intensify the treatment of small cell lung cancer? (1989) (2)
9 Radiation therapy with concurrent weekly carboplatin and paclitaxel in advanced stage unresectable squamous cell carcinomas of the head and neck (1999) (2)
Computed Tomography in the Evaluation of Lung Cancer (1986) (2)
Clinical outcomes and immune phenotypes associated with STK11 co-occurring mutations in non-small cell lung cancer (2021) (2)
Management of disseminated carcinoma of the breast (1978) (2)
Phase II Trial of N-Methylformamide in Advanced Renal Cancer (1989) (2)
Modern induction chemotherapy before chemoradiation for bulky locally-advanced nonsmall cell lung cancer improves survival. (2016) (2)
Targeted treatment of RAI-resistant metastatic thyroid cancer postcomprehensive genomic profiling. (2014) (2)
Tumor volume and treatment outcome in small cell lung carcinoma. (1989) (2)
Severe skin necrosis produced by piperazinedione extravasation. (1980) (2)
Potential applications of high-dose megestrol acetate in breast cancer. (1992) (2)
A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer (2019) (2)
Combined modalities in the treatment of small cell carcinoma of the lung. A review of current standings. (1988) (2)
Weekly paclitaxel/carboplatin and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck (1998) (1)
Current Status and Future Prospects (2017) (1)
Filtration leukapheresis (FL) and granulocytes. (1978) (1)
Specialty rounds. Management of disseminated carcinoma of the breast. (1978) (1)
Update in Combined Modality (1986) (1)
Letter: Filtration leukopheresis. (1976) (1)
Current concepts in the therapy of small cell lung cancer (1986) (1)
Association of Target Volume Margins With Locoregional Control and Acute Toxicities for Non-small cell lung cancer Treated With Concurrent Chemoradiation Therapy. (2019) (1)
Statistical Design, Monitoring, and Analysis of Clinical Trials (2021) (1)
Targeting COX-2/PG-E2 with a COX-2 inhibitor in combination with chemotherapy for non-small cell lung cancer: are we ready for phase III? (2005) (1)
P2.16-001 Liposomal Bupivacaine (Exparel) Reduces Thoracic Surgery Post-Operative Pain and Reduces Length of Stay, a Retrospetive Study (2017) (1)
Vindesine and high-dose cisplatin in the treatment of advanced non-small-cell lung cancer. (1985) (1)
Statistical Significance and p-Values (2021) (1)
Clinical activity of the selective DRD2 antagonist ONC201, an imipridone, in metastatic endometrial cancer (mEC). (2017) (1)
Ambulatory pulse oximetry as a clinical aid for the diagnosis and treatment response of radiation pneumonitis. (2015) (1)
Abstract 3513: Hydroxychoroquine (HCQ) modulates autophagy in melanoma: preliminary results of a phase 0 trial in patients with resectable melanoma. (2013) (1)
Anticancer and immunostimulatory activity of the imipridone ONC201, a selective DRD2 antagonist, in advanced cancer patients. (2017) (1)
Paclitaxel and carboplatin with simultaneous thoracic irradiation in regionally advanced non-small cell lung cancer (1997) (1)
Principles of Infection Management and Prevention (1983) (1)
Receipt of recommended surveillance with imaging in elderly survivors of early stage non-small cell lung cancer. (2018) (1)
Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer. (2006) (1)
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies (2021) (1)
In response to Dr. Ochel (2001) (1)
A phase I trial of MK-2206 and hydroxychloroquine(HCQ) in solid tumors, melanoma, renal, and prostate cancer to examine the role of autophagy in tumorigenesis. (2014) (1)
Vitamin B6 derivatives. Synthesis of N-[2-methyl-3-hydroxy-5-(2-carboxyethyl)-4-pyridylmethyl] phenylalanine and related compounds (1969) (1)
Clinical significance of pretreatment tumor growth rate for locally advanced non-small cell lung cancer. (2019) (1)
Impact of Metformin Use on Survival in Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy (2014) (1)
Breast Cancer Screening for Elderly Women-Reply (1994) (1)
Interferon alpha + 13-cis-retinoic acid modulation of BCL-2 + paclitaxel for recurrent SCLC (2008) (0)
Phase II study of medroxyprogesterone acetate with tamoxifen in advanced renal cell cancer. (1982) (0)
Phase I Clinical and Pharmacokinetic Study of Hexamethylene Bisacetamide (NSC 95580) Administered as a Five-Day Continuous Infusion1 (2006) (0)
Scientific Reporting Questioned-Reply (1978) (0)
Therapy to promote weight gain in cancer and acquired immunodeficiency syndrome patients: A panel discussion (Part 1) (1990) (0)
Pulmonary function to measure response in small cell lung cancer. (1985) (0)
Overexpression of Excision Repair Cross Complementing-1 Gene May Predict Local Recurrence After Definitive Chemoradiation for Unresectable Non-Small Cell Lung Cancer (2015) (0)
THANKS TO REVIEWERS1999 (1999) (0)
CT Evaluation of Patients During Treatment of Advanced Non‐Small Cell Lung Carcinoma (1986) (0)
Evaluation of barriers to clinical trial enrollment through a novel pharmacy quality assurance tool (2007) (0)
410 Vandetanib, docetaxel and carboplatin followed by maintenance vandetanib or placebo in patients with stage IIIB, IV or recurrent non-small cell lung cancer (NSCLC): a randomized phase II study (PrE0502) by PrECOG, LLC (NCT006872970) (2010) (0)
Thanks to authors and peer reviewers (2007) (0)
Current Approach toMalignant Mesothelioma ofthePleura (2017) (0)
A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC) (2007) (0)
Combination chemotherapy for small cell lung cancer (SCLC) with platinol, doxorubicin, cyclophosphamide and etoposide (PACE): Results of 2 studies (1989) (0)
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850 (2023) (0)
Phase I I T rial o f G emcitabine P lus C isplatin i n P atients With M etastatic U rothelial C ancer (2000) (0)
Concepts and Methods of Statistical Designs (2021) (0)
Tumor Volume Reduction Evaluated by CBCT during SBRT Treatment for Stage I/II NSCLC (2017) (0)
Treatment Approaches for Lung Cancer Patients in a Community Hospital (1986) (0)
BREAST CANCER SCREENING FOR ELDERLY WOMEN. AUTHOR'S REPLY (1994) (0)
Receipt of recommended surveillance with imaging in survivors of early stage non-small cell lung cancer. (2017) (0)
[Chemotherapy in recurrent and inoperable breast neoplasms]. (1978) (0)
Asbestos-related neoplasms. Introduction. (1981) (0)
Dose-Response T rial o f M egestrol A cetate i n A dvanced Breast C ancer: C ancer a nd L eukemia G roup B Phase I II S tudy 8 741 (1999) (0)
Author/Subject Indexes (1992) (0)
Abstract B123: A phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors (2009) (0)
FP03.02 A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients with Metastatic Non-Small Cell Lung Cancer (2021) (0)
Treatment of patients with breast cancer or prostate cancer: A panel discussion (part 2) (1990) (0)
Impact of Target Volume Margins on Locoregional Control and Acute Toxicity for Unresectable Non-Small Cell Lung Cancer (2018) (0)
Monitoring the Maximum Information and Adaptive Sample Size Designs (2021) (0)
A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)—Final report (2008) (0)
A Support Vector Machine based Prediction Model for Discrimination of Malignant Pulmonary Nodules from Benign Nodules (2016) (0)
2879 High prevalent BRAF alterations and tert promoter mutations in papillary thyroid carcinoma (2015) (0)
P-441 Weekly docetaxel (TXT) and cisplatin (CIS) for chemonaivepatients (Pts) with advanced non-small cell lung cancer (NSCLC) (2005) (0)
Survival Benefit With Carboplatin-Based Induction Chemotherapy for Bulky Stage II and III Inoperable Non-Small Cell Lung Cancer (2014) (0)
Phase I Trial of 5‐Day Continuous Infusion Aziridinylbenzoquinone (AZQ, Diazaquone, NSC 182968) (1986) (0)
An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012. (2013) (0)
Daily Image-Guidance with Cone Beam Computed Tomography May Reduce Radiation Pneumonitis in Unresectable Non-Small Cell Lung Cancer (2018) (0)
Regression Analysis of Survival Data (2021) (0)
Tumor volume reduction evaluated by cone beam computed tomography during stereotactic body radiotherapy for early stage non-small cell lung cancer (2020) (0)
A phase II clinical trial of gemcitabine and imatinib mesylate for patients with recurrent non-small cell lung cancer (NSCLC) (2008) (0)
Sequential Designs and Methods—Part II: Monitoring Safety and Futility (2021) (0)
granulocytes to sites of infection Alloimmunization prevents the migration of transfused indium-111- labeled (2011) (0)
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer (2020) (0)
Therapy for small cell and non-small cell lung cancer. (1990) (0)
Estimand, Intercurrent Events, and Missing Data (2021) (0)
Seamless Phase II/III: Select-the-Winner Design (2021) (0)
Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma (2019) (0)
Sequential Designs and Methods—Part III: Classical Group Sequential Trials (2021) (0)
Is there a therapeutic benefit for patients participating in modern phase I trials? (2011) (0)
Comparison of the demographics of patients enrolled (E) versus those not enrolled (NE) on therapeutic clinical trials at a comprehensive cancer center (2007) (0)
SCAB (streptozotocin, CCNU, adriamycin, bleomycin) for advanced untreated Hodgkin's disease (1978) (0)
P-440 Cell culture based sequenced gemcitabine (G), carboplatin (C)and paclitaxel (P); GCP for advanced stage IV non-small cell lung cancer (NSCLC) (2005) (0)
K-ras mutation for prediction of response to chemotherapy plus autophagy inhibition in NSCLC. (2014) (0)
Intravenous Gammaglobulin in Alloimmunized Platelet Transfusion Recipients (2017) (0)
P2-225: A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC) (2007) (0)
Phase i trial of 5 day continuous infusion hexamethylenebisacetamide nsc 95580 (1986) (0)
Variations in Initiation Dates of Chemotherapy and Radiation Therapy is Associated With Decreases in Overall Survival (2017) (0)
Clinical Trials with Predictive Biomarkers (2021) (0)
PB1737 MULTICENTER, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE AND FOOD EFFECT ON THE BIOAVAILABILITY OF CC-486 (ORAL AZACITIDINE) TABLETS IN ADULT CANCER PATIENTS (2019) (0)
Autophagy as a therapeutic target in cancer treatment. (2010) (0)
Overexpression of excision repair cross-complementing 1 gene associates with higher risk of therapeutic failure after definitive chemoradiation for unresectable non-small cell lung cancer. (2021) (0)
JAMA Oncology Peer Reviewers in 2017. (2018) (0)
Steroid Therapy for Acute Respiratory Distress Syndrome in Nonseptic Lobectomy Patients (2012) (0)
Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Unresectable Non-Small Cell Lung Cancer Patients (2015) (0)
Analysis of Covariance and Stratified Analysis (2021) (0)
Contents, Supplement 2, 1992 (1992) (0)
CTEP #8850: A phase I trial of riluzole and sorafenib in patients with advanced solid tumors. (2015) (0)
Clinical Characteristics and Dose Volume Histogram Parameters Associated With Pleural Effusion in Non-Small Cell Lung Cancer Patients Treated With Chemoradiation Therapy (2015) (0)
Dosimetric Predictors of Symptomatic Cardiac Events Among Patients Receiving Conventional-Dose Radiation Therapy for Inoperable Non-Small Cell Lung Cancer (2018) (0)
Training and oncologists' changing attitudes toward their own cancer therapy. (1985) (0)
Thanks to Reviewers2015 (2015) (0)
Predicting Clinical Outcomes of Patients with Stage III Non-Small-Cell Lung Cancer Treated with Concurrent Chemoradiation with and without PD-1/PD-L1 Inhibitors Using Cone Beam Computed Tomography (2020) (0)
Multiplicity Issues and Methods for Controlling the Type I Error Rate (2021) (0)
Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)—current consensus and future perspectives (2020) (0)
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors. (2019) (0)
Effect of P-30 protein and tamoxifen on transforming growth factor-β1 in patients with rising prostate specific antigen (2001) (0)
European School of Oncology First Euro-American Forum Treatment on Lung Cancer (2003) (0)
Effect of Soy Protein on Testosterone Levels (2007) (0)
JAMA Peer Reviewers in 2018. (2019) (0)
Clinical Significance of Pretreatment Tumor Growth Rate for Locally Advanced NSCLC (2017) (0)
Sequential Designs and Methods—Part I: Expected Sample Size and Two-Stage Phase II Trials in Oncology (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Joseph A. Aisner?

Joseph A. Aisner is affiliated with the following schools:

Joseph A. Aisner's Academic­Influence.com Rankings

Why Is Joseph A. Aisner Influential?

Joseph A. Aisner's Published Works

Published Works

What Schools Are Affiliated With Joseph A. Aisner?

Joseph A. Aisner's AcademicInfluence.com Rankings